These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24642991)

  • 1. VIGAS and beyond: the impact of HCMV-infection and its treatment in glioblastoma.
    Ottenhausen M; Bodhinayake I; Schaefer PM; Boockvar JA
    Neurosurgery; 2014 Apr; 74(4):N17-8. PubMed ID: 24642991
    [No Abstract]   [Full Text] [Related]  

  • 2. VIGAS and beyond: the impact of HCMV-infection and its treatment in glioblastoma.
    Ottenhausen M; Bodhinayake I; Schaefer PM; Boockvar JA
    Neurosurgery; 2014 Feb; 74(2):N23-4. PubMed ID: 24435151
    [No Abstract]   [Full Text] [Related]  

  • 3. Brain cancer. A viral link to glioblastoma?
    Miller G
    Science; 2009 Jan; 323(5910):30-1. PubMed ID: 19119195
    [No Abstract]   [Full Text] [Related]  

  • 4. Does valganciclovir have a role in glioblastoma therapy?
    Cobbs CS
    Neuro Oncol; 2014 Mar; 16(3):330-1. PubMed ID: 24523453
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects.
    Cobbs CS
    Curr Opin Oncol; 2013 Nov; 25(6):682-8. PubMed ID: 24097102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMV infection and glioma, a highly controversial concept struggling in the clinical arena.
    Wick W; Platten M
    Neuro Oncol; 2014 Mar; 16(3):332-3. PubMed ID: 24523454
    [No Abstract]   [Full Text] [Related]  

  • 7. [Inconclusive data].
    Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
    Lakartidningen; 2014 Jul 2-15; 111(27-28):1192. PubMed ID: 25162111
    [No Abstract]   [Full Text] [Related]  

  • 8. [Questionable effect of antiviral therapy in malignant brain tumors].
    Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
    Lakartidningen; 2014 Apr 29-May 13; 111(18-19):809. PubMed ID: 24855749
    [No Abstract]   [Full Text] [Related]  

  • 9. Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas?
    Wen PY
    Neuro Oncol; 2014 Mar; 16(3):329. PubMed ID: 24523452
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenging cytomegalovirus data in glioblastoma.
    Wick W; Wick A; Platten M
    Neuro Oncol; 2014 Jan; 16(1):165. PubMed ID: 24353326
    [No Abstract]   [Full Text] [Related]  

  • 11. The legend of cytomegalovirus and glioblastoma lives on.
    Weller M; Soffietti R; Brada M
    Neuro Oncol; 2014 Jan; 16(1):166. PubMed ID: 24311642
    [No Abstract]   [Full Text] [Related]  

  • 12. Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir?
    Liu CJ; Hu YW
    Int J Cancer; 2014 Jul; 135(1):250-1. PubMed ID: 24338590
    [No Abstract]   [Full Text] [Related]  

  • 13. [Questionable debate on antiviral therapy in malignant glioblastoma].
    Stragliotto G; Peredo I; Rahbar A; Andersson M; Nauclér CS
    Lakartidningen; 2014 Jul 2-15; 111(27-28):1191-2; author reply 1192. PubMed ID: 25162110
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.
    Stragliotto G; Rahbar A; Solberg NW; Lilja A; Taher C; Orrego A; Bjurman B; Tammik C; Skarman P; Peredo I; Söderberg-Nauclér C
    Int J Cancer; 2013 Sep; 133(5):1204-13. PubMed ID: 23404447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir.
    Söderberg-Naucler C; Peredo I; Rahbar A; Hansson F; Nordlund A; Stragliotto G
    Int J Cancer; 2014 Jul; 135(1):248-9. PubMed ID: 24338548
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytomegalovirus and glioblastoma: a review of evidence for their association and indications for testing and treatment.
    Solomon IH; Ramkissoon SH; Milner DA; Folkerth RD
    J Neuropathol Exp Neurol; 2014 Nov; 73(11):994-8. PubMed ID: 25289896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival.
    Rahbar A; Orrego A; Peredo I; Dzabic M; Wolmer-Solberg N; Strååt K; Stragliotto G; Söderberg-Nauclér C
    J Clin Virol; 2013 May; 57(1):36-42. PubMed ID: 23391370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of human cytomegalovirus reactivation in newly diagnosed glioblastoma patients treated with chemoradiotherapy.
    Ursu R; Doridam J; Chaugne E; Zannou H; Belin C; Cuzzubbo S; Sirven-Villaros L; Brichler S; Levy-Piedbois C; Carpentier AF
    J Neurovirol; 2021 Feb; 27(1):94-100. PubMed ID: 33405205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of human cytomegalovirus expression in single cells from glioblastoma tumors and cell lines.
    Johnson TS; Abrams ZB; Mo X; Zhang Y; Huang K
    J Neurovirol; 2017 Oct; 23(5):671-678. PubMed ID: 28695489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Valganciclovir maintenance therapy in AIDS: treatment failure due to the development of cytomegalovirus resistance to ganciclovir].
    Couzigou C; Mazeron MC; Escaut L; Merad M; Vittecoq D
    Med Mal Infect; 2005 Feb; 35(2):98-100. PubMed ID: 15780901
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.